Psoriasis – Unmet Need – Unmet Need – Moderate to Severe Psoriasis (US/EU)

Topical therapies are the backbone of psoriasis management; however, they are often inadequate for patients with moderate to severe disease, who typically require systemic treatment. While conventional systemic agents and TNF-α inhibitors historically dominated early-line therapy, recent years have seen a gradual shift toward earlier use of non-TNF biologics, particularly IL-17 inhibitors (e.g., Cosentyx, Taltz, Bimzelx) and IL-23 inhibitors (e.g., Tremfya, Skyrizi), driven by their superior efficacy and more favorable long-term safety profiles. The market has further expanded with the increased uptake of oral targeted therapies, including PDE4 inhibitor Otezla and, more recently, the oral TYK2 inhibitor Sotyktu, offering non-injectable options for psoriasis patients. Despite the availability of multiple treatments for psoriasis, a substantial unmet need remains. Novel agents are needed that can differentiate on the attributes of efficacy, safety, delivery, and ability to treat a broad patient population.

QUESTIONS ANSWERED

• How do dermatologists rate the performances of Bimzelx, Sotyktu, and their competitors on key treatment drivers and goals for moderate to severe psoriasis?
• Which clinical and nonclinical attributes are key influencers of dermatologists’ prescribing decisions, and which have limited impact? What are areas of hidden opportunity?
• What are the key unmet needs and leading opportunities in the treatment of moderate to severe psoriasis?
• What trade-offs across key clinical / nonclinical attributes and price are acceptable to U.S. and European dermatologists for a hypothetical new drug for moderate to severe psoriasis?

PRODUCT DESCRIPTION

Unmet Need offers insight into key treatment drivers and goals, the performance of current therapies, and the remaining commercial opportunities, enabling you to:

• Evaluate clinical and nonclinical product attributes that influence treatment decisions through physicians’ weightings and analysis of stated vs. derived importance.
• Pinpoint areas of high unmet need by assessing current drug performance against key attributes and treatment drivers.
• Analyze market scenarios for different target product profiles using the TPP Simulator.

Markets covered: United States, United Kingdom, France, Germany

Primary research: Survey of 61 U.S. and 30 European dermatologists

Key drugs: Humira, Stelara, Taltz, Bimzelx, Skyrizi, Otezla, Sotyktu

Key analyses

• Importance of clinical and nonclinical product attributes to physicians
• Assessment of current drug performance against treatment drivers and goals
• Physician perceptions of unmet needs in the indication and related indications
• Remaining drug development opportunities